Health Care/Hospital Global News & Press Release Distribution

Health Care/Hospital

All
APAC

Keymed Biosciences Announces Interim Results for First Half of 2024

CHENGDU, China , Aug. 27, 2024 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) today announced its interim results for the first half of 2024, along with a corporate update. Rapid development of our pipeline products Stapokibart (CM310) (IL-4Rα antibody) * In June 2024, the long-term e...

2024-08-27 21:10 2061

Sleep Specialists and Industry Leaders Converge at HoneyNaps Symposium

* The 1st HoneyNaps Sleep & Tech Symposium * Presentation of the 'SLEEP 2024 White Paper' and the Latest Advances in Sleep Research & Technology * Unveiling of HoneyNaps' New Brand Identity BOSTON, Aug. 27, 2024 /PRNewswire/ -- HoneyNapsUSA, Inc., an AI-driven sleep data analysis company, p...

2024-08-27 21:00 1849

Sleep Specialists and Industry Leaders Converge at HoneyNaps Symposium

111, Inc. to Participate in Fireside Chat with Water Tower Research on September 5, 2024

SHANGHAI, Aug. 27, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream inChina, today announced that it will parti...

2024-08-27 20:00 1437

YolTech Announces Licensing Agreement with Salubris for the Development and Commercialization of YOLT-101 in Mainland China

SHANGHAI, Aug. 27, 2024 /PRNewswire/ -- YolTech Therapeutics, a pioneering clinical-stage gene editing company dedicated to delivering lifelong cures, announced today that it has entered into an exclusive licensing agreement with Salubris Pharmaceuticals Co., Ltd. (stock code: 002294.SZ), a leadi...

2024-08-27 18:30 1155

HKBU research identifies potential of phosphocholine in counteracting PM2.5 toxicity in lung diseases

HONG KONG, Aug. 27, 2024 /PRNewswire/ -- A research team led by Hong Kong Baptist University (HKBU) has discovered that phosphocholine, an important component in the body's metabolism, could counteract the adverse effects of PM2.5 toxicity on lung cells. This discovery highlights the therapeutic ...

2024-08-27 13:28 1746

HKBU research identifies potential of phosphocholine in counteracting PM2.5 toxicity in lung diseases

Mabwell Announces CDE Approval to Initiate Phase III Clinical Trial of 9MW2821 for Urothelial Carcinoma in Combination with PD-1 Inhibitor

SHANGHAI, Aug. 26, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that its submission to the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) for "a randomized, controlled, open-label, ...

2024-08-26 22:00 1920

Actinogen announces further positive results on depression in the XanCIDD phase 2a trial

Durable benefits previously reported for the MADRS depression scale are supported by the patient-reported outcome of PGI-S and new MADRS responder analyses that underscore benefit at week 10 with a 50% higher rate of remission of depression SYDNEY, Aug. 26, 2024 /PRNewswire/ -- Actinogen Medic...

2024-08-26 20:30 1537

Peijia Medical Announces 2024 Interim Results

HONG KONG, Aug. 26, 2024 /PRNewswire/ -- Peijia Medical (HKG:9996), a leading Chinese domestic player in the high-growth transcatheter valve therapeutics and neurovascular interventions markets, announced financial results for the six months endedJune 30, 2024 ("the period") on August 23, 2024. ...

2024-08-26 20:30 2183

I-Mab to Participate at the H.C. Wainwright 26th Annual Global Investment Conference

ROCKVILLE, Md., Aug. 26, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB), a US-based, global, clinical-stage biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced that management will present at the H.C. Wainwright ...

2024-08-26 19:00 1014

Meihua International Medical Technologies Co., Ltd. to Present at LIVE! with Webull Corporate Connect: Virtual Healthcare Investment Webinar on August 28, 2024

YANGZHOU, China, Aug. 26, 2024 /PRNewswire/ -- Meihua International Medical Technologies Co., Ltd. ("MHUA" or the "Company") (Nasdaq: MHUA), a reputable manufacturer and provider of Class I, II, and III disposable medical devices with operating subsidiaries inChina, today announced that Xin "Stev...

2024-08-26 18:00 1614

Mabwell Announces the CDE Approval of Novel Nectin-4 Targeting ADC to Initiate Phase III Clinical Trial for the Treatment of Cervical Cancer

SHANGHAI, Aug. 23, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that its submission to the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) for the "A Randomized, Open-label, Phase II...

2024-08-23 22:00 5007

CanariaBio Inc Announces Enrollment Completion of randomized Phase 2 study of Oregovomab in combination with chemotherapy as neo-adjuvant treatment of patients with Advanced Ovarian Cancer

SEOUL, South Korea, Aug. 23, 2024 /PRNewswire/ -- CanariaBio Inc, a leading late-stage biotechnology company, announces the successful completion of enrollment of 88 patients in a randomized Phase 2 study of oregovomab in combination with chemotherapy (paclitaxel and carboplatin)as neo-adjuvant ...

2024-08-23 20:00 4631

GenFleet Announces the First Approval of a KRAS G12C Inhibitor in China for Treatment of Advanced Non-small Cell Lung Cancer Patients Harboring KRAS G12C Mutation

SHANGHAI, Aug. 23, 2024 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, announcedChina's National Medical Products Administration has approved Dupert®（fulzerasib, GFH925/IBI351）for the treatment of patien...

2024-08-23 19:30 3884

Corina Intrauterine Drug-Eluting System approved in China as a novel treatment for patients with moderate-to-severe intrauterine adhesions (IUA)

The World's First-in-Class Intrauterine Drug-Eluting System SHANGHAI, Aug. 23, 2024 /PRNewswire/ -- Corina Intrauterine Drug-Eluting System ("Corina"), developed by Yipurun (Shanghai) Biotechnology Co., Ltd. ("YPR"), has received approval inChina (G.X.Z.Z. 20243181461) for use in patients with ...

2024-08-23 18:45 2585

Corina Intrauterine Drug-Eluting System approved in China as a novel treatment for patients with moderate-to-severe intrauterine adhesions (IUA)

Bridge Biotherapeutics and HitGen Initiate Research Collaboration to Advance Novel Cancer Therapeutics Program

* Bridge Biotherapeutics Enters into a joint research agreement with the Chinese drug discovery platform company "HitGen" to accelerate the discovery of new drug candidates for a FIC novel cancer therapeutics program * Aims to strengthen its oncology portfolio with a novel drug candidate for ...

2024-08-22 21:30 1988

Ubie Announces Social Impact Framework, Shows Estimated Patient Life Expectancy Impact of 27,000 Years and Approximately $1BN

* Ubie has taken the lead in implementing a new standard of measurement to evaluate health and economic impact for global digital health startups * The framework uses the pharmaceutical industry's standard of Quality-Adjusted Life Years (QALY) to provide a widely-accepted and transparent impa...

2024-08-22 21:30 1399

Clarity receives FDA Fast Track Designation for 64Cu-SAR-bisPSMA

SYDNEY, Aug. 22, 2024 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce that the U.S. Food and ...

2024-08-22 21:04 2036

Stem Cell Therapy developers I Peace and iCamuno Biotherapeutics Start Natural Killer Cell Trial for Ovarian Cancer

PALO ALTO, Calif., Aug. 22, 2024 /PRNewswire/ -- I Peace, a pioneering CDMO in induced pluripotent stem (iPS) cells, and iCamuno Biotherapeutics, a biotech company developing iPS cell-based therapies, today announced a significant milestone with the dosing of the first patient in a clinical trial...

2024-08-22 21:00 1328

Ractigen Therapeutics Announces U.S. FDA Orphan Drug Designation (ODD) granted to RAG-18 for the treatment of Duchenne Muscular Dystrophy and Becker Muscular Dystrophy

NANTONG and SUZHOU, China, Aug. 22, 2024 /PRNewswire/ -- Ractigen Therapeutics, a pioneering developer of small activating RNA (saRNA) therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to RAG-18, one of the company's lead saRN...

2024-08-22 20:00 1590

YolTech Therapeutics Administers First Patient Dose in IIT of YOLT-203, the World's First In Vivo Gene Editing Therapy for PH1

SHANGHAI, Aug. 22, 2024 /PRNewswire/ -- YolTech Therapeutics, a pioneering clinical-stage gene editing company dedicated to delivering lifelong cures, today announced a major milestone: the first patient has been dosed with YOLT-203, the company's cutting-edge in vivo genome editing candidate. Th...

2024-08-22 18:00 1667

1 ... 16 17 181920 21 22 ... 277